Replies to post #149462 on Biotech Values

[mcbio]

IMGN has an ADC in ph1, IMGN853 targeting folate receptor positive OC and other solid tumors.

I believe ECYT said in their recent CC that IMGN is not using a companion diagnostic to specifically target patients. Would seem to be a disadvantage relative to ECYT's approach.

[bladerunner1717]

I knew you would know, jq. LOL

It seems the IMGN drug is in direct competition to ECYT's EC145. Do you agree?


Bladerunner